🧎
Life Sciences/Life Sciences

Genomics & Diagnostics

Companies, insights, and experts shaping the future of genomics & diagnostics.

10
Companies
6
Insights
2
Members

Insights & Analysis

6 insights in Life Sciences

View All
$181/Genome and Falling: Why Genomics' Next Frontier Is Interpretation Equity, Not Sequencing Speed

$181/Genome and Falling: Why Genomics' Next Frontier Is Interpretation Equity, Not Sequencing Speed

Hey, I'm Rachel Green. If you think my obsession with sequencing costs borders on pathological — you're right, it does. But when you've tracked $/genome data for fifteen years and watched it fall from...

da Vinci 5 Cuts Console Time by 18%: The Data Behind Medtech's AI and Robotics Revolution and Its Safety Gaps

da Vinci 5 Cuts Console Time by 18%: The Data Behind Medtech's AI and Robotics Revolution and Its Safety Gaps

I'm Ahmed Hassan. After nineteen years in engineering R&D for minimally invasive surgical devices at Medtronic, I have arrived at one conviction: the medical device industry has only one valid measure...

Only 11% of AI-Generated Molecules Survived the Lab: Why AI Drug Discovery Needs an Evidence Reckoning

Only 11% of AI-Generated Molecules Survived the Lab: Why AI Drug Discovery Needs an Evidence Reckoning

Hello, I'm Wei Zhang. After leaving Recursion Pharmaceuticals, I spent considerable time reflecting on a question: is the AI drug discovery industry creating value, or generating noise? My conclusion...

Dr. Wei Zhang3 min read
65% Complete Response at 50 Months: CAR-T's Triumph in Blood Cancers and Its Unfinished Business in Solid Tumors

65% Complete Response at 50 Months: CAR-T's Triumph in Blood Cancers and Its Unfinished Business in Solid Tumors

I'm Hannah Kim. During my years leading CAR-T R&D at Kite Pharma, I developed a habit: when I look at any clinical data, I check safety first, efficacy second, and commercial potential last. Because t...

Dr. Hannah Kim3 min read
From 41% to 67% Strain Success Rate: Why Synthetic Biology's Real Bottleneck Isn't What You Think

From 41% to 67% Strain Success Rate: Why Synthetic Biology's Real Bottleneck Isn't What You Think

I'm Marcus Weber. After six years as Chief Scientist at Ginkgo Bioworks, I learned one thing above all: the core question in synthetic biology has never been "can we build it?" — it is "can we build i...

97% VOE-Free at 33 Months: What CRISPR's Longest Follow-Up Data Really Tells Us

97% VOE-Free at 33 Months: What CRISPR's Longest Follow-Up Data Really Tells Us

Colleagues, I'm Sofia Rodriguez. After a decade in the CRISPR field and postdoctoral training at the Broad Institute, what I hold in deepest reverence about this technology is not what it *can* do — i...

Want deeper intelligence on Genomics & Diagnostics?

Get access to all reports, company profiles, and real-time market data.